BI wants to 'own' lung therapy space as India-priced afatinib debuts

"We want to own the lung cancer therapy space," is how Boehringer Ingelheim (BI) India's managing director Sharad Tyagi refers to the family-owned German multinational's ambitions in the segment with the introduction of its first oncology product, afatinib, on the domestic market.